J.C is an 82-year-old white man who was evaluated by GI specialist due to abdominal discomfort, loss of appetite, weight lost, weakness and occasional nausea.
Past Medical History (PMH):
Patient is Diabetic, controlled with Metformin 500 mg by mouth twice a day, Lantus 15 units SC bedtime. Hypertensive, controlled with Olmesartan 20 mg by mouth once a day. Atrial Fibrillation, controlled with Rivaroxaban 15 mg by mouth once a day and bisoprolol 10 mg by mouth once a day.
Labs:
Hb 12.7 g/dl; Hct 38.8% WBC 8.2; Glycemia 74mg/dl; Creatinine 0.8 mg/dl; BUN 9.8 mg/dl; AST 21 U/L ALT 17 U/L; Bil T 1.90 mg/dl; Ind 0.69 mg/dl; Dir 1.21 mg/dl.
Diagnostic test:
Endoscopic Ultrasound of the Pancreas. Solid mass in the head of pancreas 4 cms, infiltrating Wirsung duct. The solid mass impress to infiltrate the superior mesenteric vein. Perilesional node is detected, 1.5 cms, metastatic aspect. Fine needle aspiration (FNA) biopsy: Ductal adenocarcinoma.
Case study questions:
- Please name the potential most common sites for metastasis on J.C and why?
- What are tumor cell markers and why tumor cell markers are ordered for a patient with pancreatic cancer?
- Based on the case study described, proceed to classify the tumor based on the TNM Stage classification. Why this classification important?
- Discussed characteristic of malignant tumors regarding it cells, growth and ability to spread.
- Describe the carcinogenesis phase when a tumor metastasizes.
- Choose the tissue level that is affected on the patient discussed above: Epithelial, Connective, Muscle or Neural. Support your answer. J.C is an 82-year-old white man
Submission Instructions:
- Your initial post should be at least 500 words, formatted and cited in current APA style with support from at least 2 academic sources.
**Metastasis Sites in Pancreatic Cancer**
- **Liver:** The liver is one of the most common sites for metastasis in pancreatic cancer due to the close proximity of the liver to the pancreas and the extensive blood supply to the liver. Metastasis to the liver can occur through the bloodstream or lymphatic system, leading to the formation of secondary tumors in the liver.
- **Peritoneum:** Pancreatic cancer can spread to the peritoneum, the membrane lining the abdominal cavity, through direct extension or via peritoneal fluid. Peritoneal metastasis can cause symptoms such as ascites (fluid buildup in the abdomen) and abdominal pain.
- **Lungs:** Metastasis to the lungs is also common in pancreatic cancer, typically occurring through hematogenous spread. Lung metastases can lead to respiratory symptoms such as cough, shortness of breath, and chest pain.
- **Lymph Nodes:** Pancreatic cancer often spreads to nearby lymph nodes, particularly those in the peripancreatic region, as well as distant lymph nodes such as those in the abdomen, chest, and supraclavicular area. Lymph node involvement is associated with advanced disease and poorer prognosis.
**Tumor Cell Markers in Pancreatic Cancer**
Tumor cell markers are substances produced by cancer cells or by the body in response to cancer. In pancreatic cancer, tumor cell markers such as CA 19-9 and CEA (carcinoembryonic antigen) are commonly ordered for diagnostic and prognostic purposes. These markers can help in the detection of pancreatic cancer, monitoring treatment response, and assessing disease progression. Elevated levels of CA 19-9 and CEA in the blood are associated with pancreatic cancer and may indicate the presence of tumor burden or metastasis.
**TNM Stage Classification**
Based on the TNM Stage classification system, the tumor described in the case study can be classified as follows:
– T: T4 (tumor extends beyond the pancreas and involves nearby structures such as the superior mesenteric vein)
– N: N1 (regional lymph node involvement)
– M: M1 (distant metastasis to perilesional node)
This classification is important because it helps in determining the extent of the disease, guiding treatment decisions, and predicting prognosis. TNM staging provides valuable information for clinicians to assess the severity of the cancer and plan appropriate management strategies.
**Characteristics of Malignant Tumors**
Malignant tumors exhibit several characteristics, including:
– **Abnormal Cell Growth:** Malignant tumors display uncontrolled and abnormal cell growth, leading to the formation of a mass or tumor.
– **Invasion:** Malignant tumors have the ability to invade surrounding tissues and structures, compromising their function and integrity.
– **Metastasis:** Malignant tumors can spread to distant sites in the body through the bloodstream or lymphatic system, forming secondary tumors or metastases.
– **Angiogenesis:** Malignant tumors stimulate the formation of new blood vessels (angiogenesis) to supply nutrients and oxygen, promoting tumor growth and metastasis.
– **Genetic Instability:** Malignant tumors exhibit genetic instability, with alterations in DNA contributing to tumor progression, heterogeneity, and resistance to treatment.
**Carcinogenesis and Metastasis**
Carcinogenesis is the process by which normal cells transform into cancer cells. When a tumor metastasizes, cancer cells from the primary tumor invade surrounding tissues and enter blood vessels or lymphatic vessels, allowing them to travel to distant sites in the body. At the metastatic site, cancer cells proliferate and form secondary tumors, establishing new colonies of cancer cells. The process of metastasis involves multiple steps, including invasion of surrounding tissues, intravasation into blood or lymphatic vessels, circulation through the bloodstream or lymphatic system, extravasation into distant tissues, and colonization of secondary sites.
**Tissue Level Affected**
In the case described above, the tissue level affected is the connective tissue. Pancreatic cancer originates in the epithelial cells of the pancreas and can infiltrate and invade the surrounding connective tissue, including blood vessels, lymphatic vessels, and nerves. Metastasis of pancreatic cancer to distant sites also involves invasion and colonization of connective tissue in secondary organs such as the liver, lungs, and peritoneum.
References:
- Rawla, P., & Sunkara, T. (2019). Pancreatic cancer: Epidemiology, genetics, and therapy. Anticancer Research, 39(12), 6269–6274.
- Zhang, L., & Sanagapalli, S. (2021). Biomarkers in pancreatic cancer: Diagnostic, prognostic, and predictive significance. Cancer Letters, 510, 10–18.
"Place your order now for a similar assignment and have exceptional work written by our team of experts, guaranteeing you "A" results."
